Clare McGrane
Clare McGrane is a GeekWire reporter specializing in life sciences, biotechnology, and technology, and produces the GeekWire radio show and podcast.
Recent coverage
Front-page news, podcasts and videos about Clare
AdaptX (formerly MDMetrix) raises $6M Series A led by Vulcan Capital to expand AI-driven healthcare data platform
AdaptX, formerly MDMetrix, raised $6 million in a Series A led by Vulcan Capital to expand its AI-driven platform that extracts insights from electronic medical records to improve clinical, financial and equity outcomes. The Seattle startup, founded by anesthesiologist Dr. Dan Low, has raised over $11 million total, employs about 20 people, and will use proceeds for hiring and product development.
MDMetrix and TransformativeMed Offer Free COVID-19 Tracking Tools to Hospitals; Deployed at UW Medicine
Two Seattle startups, MDMetrix and TransformativeMed, are offering their combined COVID-19 patient-tracking and analysis tools free to hospitals so clinicians can spot treatment and spread trends across patient groups. Their systems are already in use at University of Washington Medicine to screen patients, track symptoms and labs, and report data to state health departments.
By Clare
See all 7ApoGen Raises $4M More in Series A to Combat Drug-Resistant Cancers, Adds Biotech Vets to Leadership
Biotech startup ApoGen raised an additional $4 million in its Series A round, totaling $11 million, to advance its development of treatments for drug-resistant cancers. The company also expanded its executive team by hiring Seattle biotech veteran Peter de Vries and added M Ventures' Investment Director Keno Gutierrez to its board.
Nelson Del Rio Joins Seattle Startup Blokable as Co-CEO to Advance Scalable Affordable Housing Solutions
Nelson Del Rio has joined Seattle startup Blokable as co-CEO, working alongside co-founder Aaron Holm to develop scalable modular housing solutions for affordable housing. Del Rio brings expertise in public-private partnerships and aims to transform the residential housing development process amid the ongoing housing crisis.
M3 Biotechnology Secures $1.4M from Alzheimer’s Drug Discovery Foundation to Launch Clinical Trials for Innovative Alzheimer's Therapy
Seattle-based M3 Biotechnology secured an additional $1.4 million from the Alzheimer’s Drug Discovery Foundation to prepare clinical trials for its novel Alzheimer’s therapy aimed at stopping neuron deterioration. This funding follows a previous $14 million raised, supporting the company’s advancement toward potentially halting disease progression rather than just treating symptoms.
